Similarly, studies have also shown that combined RAF-MEK inhibition would overcome ERK reactivation in KRAS mutant or wild type cancer lines (Lamba et al., 2014; Yen et al., 2018), implicating this as a potential strategy for PDAC. The gene discussed is RAF1; the disease is cancer.